Table 1 Clinical and sociodemographic characteristics of the sample

Age

62.5 ± 8.6

35–75

Disease duration (months)

5.52 ± 6

0–114

UPDRS-III^a (off)

21.9 ± 11

2–78

H&Y^b (off)

2

1–4

 Stage 1

14.7%

–

 Stage 1.5

9.2%

–

 Stage 2

60%

–

 Stage 2.5

7.1%

–

 Stage 3

7.8%

–

 Stage 4

1.3%

–

LDD^c

527 ± 420

0–2220

DA^d equivalent daily dose

182 ± 172

0–1387

PD-CRS^e Total

91.8 ± 15.4

44–135